Quadruple Therapy for Triple Therapy Resistant Helicobacter Pylori Infection
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
Triple therapy, a combination of proton pump inhibitor with two antibiotics, is the gold
standard for anti-Helicobacter pylori treatment. Usual antibiotics are clarithromycin, and
either amoxicillin or one of the nitroimidazoles (metronidazole). However, there is an
increasing evidence of H. pylori resistance to classical triple therapy. Another reason for
this failure being low patient compliance with treatment. A regimen useful in one
geographical area may not be effective or practical in another area. The aim of this study
was to eradicate H. pylori infection resistant to triple therapy, establish the efficacy and
safety of a 14-day therapeutic regimen to eradicate of H. pylori in patients who have failed
with the classical triple therapy (omeprazole, clarithromycin and amoxicillin) given for 14
days.